Incyte
INCY
#1136
Rank
NZ$33.93 B
Marketcap
NZ$172.83
Share price
0.20%
Change (1 day)
39.86%
Change (1 year)

P/E ratio for Incyte (INCY)

P/E ratio as of December 2025 (TTM): 16.5

According to Incyte's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 16.4624. At the end of 2024 the company had a P/E ratio of 223.

P/E ratio history for Incyte from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024223847.43%
202323.5-54.91%
202252.2204.83%
202117.1-127.34%
2020-62.6-249.06%
201942.0-65.67%
2018122-301.43%
2017-60.7-133.91%
2016179-96.7%
2015> 1000-2325.07%
2014-244159.92%
2013-93.8103.21%
2012-46.1

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Amgen
AMGN
25.4 54.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Ligand Pharmaceuticals
LGND
82.6 401.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
52.3 217.72%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
14.5-11.69%๐Ÿ‡บ๐Ÿ‡ธ USA
Geron
GERN
-11.2-167.83%๐Ÿ‡บ๐Ÿ‡ธ USA
Ardelyx
ARDX
-25.0-252.13%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
18.9 14.68%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
AVEO Oncology
AVEO
-17.9-208.47%๐Ÿ‡บ๐Ÿ‡ธ USA
CTI BioPharma
CTIC
-15.7-195.20%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.